Rethinking global pricing strategies through the most-favored nation lens
As attention grows around the Most-Favored Nation (MFN) policy, this Deep Dive analyzes how MFN is evolving across prior executive actions, emerging pricing models and current industry activity. Based on the session at ISPOR Europe 2025, it provides a practical roadmap for planning under uncertainty and guidance for manufacturers navigating MFN.
Contents:
- Setting the stage: MFN – “the gift that keeps on giving”
- What previous executive orders reveal about MFN’s feasibility
- Designing MFN: The emerging international reference pricing model
- The price comparison problem: Which prices are likely to be compared?
- Navigating the international price convergence component of the MFN: Practical actions for manufacturers
- DTC platforms and US investment: The other two pillars of MFN
About the speaker
Tim Wright
Executive Vice President, Access and Pricing, Genesis Research Group
Tim Wright leads the Access & Pricing division at Genesis Research Group. An economist and health economist, Tim has 30 years of experience in the biopharma sector, including 18 years in executive positions in strategic consulting firms and 12 years in global EU and UK roles in industry. In consulting, Tim has provided strategic leadership in over 1000 engagements with small biotechs to top-five pharma and across all therapy areas. Within the industry, Tim was responsible for global pricing and access strategy for two mega-brands and the CV, respiratory, infection and inflammation early asset portfolio at AstraZeneca. He is former Head of HEOR at Janssen Cilag UK, and brings experience from EU Pricing for Allergan and his time as a clinical scientist at Astra.
Sponsorship for this Deep Dive was provided by Genesis Research Group.